Appendix S2

Patient characteristics per biologic treatment

	Biologics (*n* = 100)				
	Adalimumab *n* = 35	Etanercept *n* = 31	Ustekinumab *n* = 27	*p*[d]	Infliximab *n* = 7
Patient general characteristics					
Age, years, mean±SD	48.46±12.8	52.2±14	53.3±12.3	0.31	54.4±15.7
Male sex, *n* (%)	26 (74.3)	23 (74.2)	17 (63)	0.60	2 (28.6)
Age at onset of psoriasis, years, median (range)	20 (1–43)	22 (6–56)	29 (13–61)	0.18	30 (9–55)
PASI at the time of the survey, median (range)	1.8 (0–9.6)	4 (0–16.2)	3.8 (0–14.3)	**0.003**	5.8 (1.2–13.5)
Diagnosis of PsA, yes, *n* (%)	9 (25.7)	8 (25.8)	6 (22.2)	0.94	1 (14.3)
Disease duration at the time of the survey, years, mean±SD	26.2±12.8	29 ±13.3	23.5±12.5	0.27	21.4±11.2
Age at start treatment, mean±SD	45.1±12.9	46.7±13.3	52.9±12.2	0.06	53.1±15.3
Treatment duration, years, median (range)	2.9 (0.1–6.8)	5.9 (0.1–10.3)	1.3 (0.06–5.7)	**0.0001**	0.7 (0.39–2.8)
History of psoriasis therapies[a]					
Number of conventional systemic therapies[b], *n* (%)					
0	1 (2.9)	1 (3.2)	0 (0)	0.16	0 (0)
1	3 (8.6)	4 (12.9)	2 (7.4)		0 (0)
2	5 (14.3)	14 (45.2)	12 (44.4)		3 (42.9)
3	20 (57.1)	9 (29)	9 (33.3)		4 (57.1)
4	6 (17.1)	3 (9.7)	4 (14.8)		0
Number of biologic therapies[c], *n* (%)					
0	16 (45.7)	18 (58.1)	3 (11.1)	**0.004**	1 (14.3)
1	14 (40)	8 (25.8)	9 (33.3)		0 (0)
2	3 (8.6)	4 (12.9)	11 (40.7)		1 (14.3)
3	2 (5.7)	1 (3.2)	3 (11.1)		4 (57.1)
4	0 (0)	0 (0)	1 (3.7)		1 (14.3)
Phototherapy, *n* (%)					
Yes	33 (94.3)	30 (96.8)	26 (96.3)	0.87	7 (100)
No	2 (5.7)	1 (3.2)	1 (3.7)		0 (0)

[a]Therapies are counted only once per patient, regardless of the number of times they were prescribed. [b]Conventional systemic therapies: acitretin, cyclosporine, fumarates or methotrexate. [c]Biologic therapies: adalimumab, alefacept, etanercept, infliximab or ustekinumab. [d]*p*-values of adalimumab, etanercept and ustekinumab. Infliximab was not included in this analysis due to the small number of exposed patients

All data were included. No missing values were found. Significant *p*-values (*p* < 0.05) are shown in bold. PASI: Psoriasis Area and Severity Index; PsA: psoriatic arthritis; SD: standard deviation.